 |
|
|
|
|
|
||
      |
|
||
 |
 |
|
|
|
|||
 |
Stanford SYSTEMS NEUROSCIENCE & Pain Lab |
Low Dose Naltrexone for the
Dr. Jarred Younger, PhD and Dr. Sean Mackey, MD, PhD, of the Stanford Systems Neuroscience and Pain Lab are currently enrolling patients for a clinical trial investigating low-dose naltrexone for the treatment of fibromyalgia.
Fibromyalgia Symptoms
The primary complaint of those with fibromyalgia is widespread body pain and muscle tenderness. Most people who have fibromyalgia also experience fatigue and have trouble sleeping. They may also complain of concentration or memory problems, gastrointestinal issues, headaches, and muscle weakness.
Role of Low-Dose Naltrexone
At normal doses (50mg – 100mg), naltrexone is a drug used to block the effects of opioids. At low (<5mg) doses, however, the drug may have the reverse effect and actually strengthen analgesia. While the exact mechanism of this action is unknown, it is possible that low doses of naltrexone block the receptors on glial cells that are responsible for fibromyalgia symptoms. The drug has been used for many years off-label for the treatment of fibromyalgia, and this is the first clinical study of the drug in fibromyalgia.
This study is being funded by the non-profit organization: the American Fibromyalgia Syndrome Association (AFSA). There are no pharmaceutical industry or business interests involved in this study.
For more information about the study, including eligibility criteria, follow the link below to the study information page, or download the study brochure.
If you are interested in participating, please complete the secure screening survey by clicking on the link below.
COMPLETE THE SCREENING QUESTIONNAIRE
